| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Autoimmune demyelinating neuropathies include several conditions — among them chronic inflammatory demyelinating polyneuropathy (CIDP), autoimmune nodopathy, Guillain-Barre syndrome (GBS), distal acquired demyelinating symmetric (DADS) neuropathy, chronic immune sensory polyradiculopathy (CISP), and multifocal motor neuropathy (MMN) — that share overlapping motor and/or sensory features with other peripheral neuropathies.
Used as an adjacent to nerve conduction study (NCS) and electromyography (EMG) studies, our testing can help physicians better understand the underlying etiology of a patient’s demyelinating neuropathy, which is important to accurately diagnose and treat patients.
Demyelinating neuropathies Test menu
When NCS and EMG studies are suggestive of a demyelinating process, the presence of specific autoantibodies indicates that an underlying, misdirected immune response may be driving the demyelination. Our clinically validated antibody evaluation includes only those biomarkers that correlate with demyelinating neuropathies. Including wide-ranging, relevant antibodies with high clinical specificity minimizes unnecessary testing and the potential for false-positive results.
Key testing
Advantages
Highlights
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.
Frequently misdiagnosed, CIDP in most cases is highly responsive to first-line immunotherapy treatments, such as intravenous immunoglobin (IVIG). However, a subset of individuals with specific paranodal antibodies do not respond as well to these therapies. The presence of neurofascin 155 (NF155) IgG4 and contactin-1 (CNTN1) IgG indicates a unique disease etiology with antibodies targeting the paranode. These patients have relatively poor treatment response to IVIG. We’ve developed and validated a unique assay combination available exclusively at Mayo Clinic Laboratories.
Key testing
Advantages
Highlights
Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide treatment decisions. Often misdiagnosed, CIDP is treatable if detected early.
Sophisticated laboratory testing solved a medical riddle and finally got Jori Pearson back on his feet, doing what he loves.
The presence of myelin associated glycoprotein (MAG) antibodies is often linked to a rare demyelinating neuropathy with poor treatment response known as DADS neuropathy. In some cases, reaching correct diagnosis through clinical and electrophysiological evaluation alone can be difficult due to overlapping features, or when patient evaluation occurs later in the disease course. Incorporating MAG antibody testing into the diagnostic workup can help identify the correct diagnosis and exclude patients with treatable immune-mediated neuropathies.
Key testing
Advantages
Highlights
John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat condition known as DADS neuropathy.